ネクセラファーマ(株)【4565】の掲示板 2018/08/16〜2018/08/21
-
1114
***
2018年8月21日 22:12
>>1113
お前、やっぱ baka だったな。
これ以上、ボケ老人とコメントしても意味がないよ。
だから、言ったろ、「フェーズⅠ・フェーズⅡa」を通しで行う試験だって。
アッフォー・アッフォー
> どこにフェーズ1完了とかいているのか？
> Study Type : Interventional (Clinical Trial)
> Estimated Enrollment : 51 participants
> Intervention Model: Single Group Assignment
> Masking: None (Open Label)
> Primary Purpose: Treatment
> Official Title: A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer
> Actual Study Start Date : March 1, 2016
> Estimated Primary Completion Date : September 2018
> Estimated Study Completion Date : December 2018 -
1115***
2018年8月21日 22:13
>>1113
Ｇｏｏｇｌｅ翻訳使って、この英文を理解したらどうだ。
MiNA’s first clinical asset has successfully completed Phase 1 and MiNA is developing a pipeline of therapeutic opportunities.
どこにフェーズ1完了とかいているのか？
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 51 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer
Actual Study Start Date : March 1, 2016
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : December 2018